Botulinum Neurotoxin Antibody Combinations for Broad Serotype Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for botulism, caused by botulinum neurotoxins, lack specific small molecule drugs and existing monoclonal antibody therapies face challenges due to serotype variability and limited cross-reactivity, making mass vaccination and treatment ineffective against multiple serotypes.
Innovation Solution
Development of neutralizing antibodies that bind multiple botulinum neurotoxin serotypes with high affinity, including combinations of antibodies targeting different subtypes and epitopes, to provide broad-spectrum protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibody therapies are developed to treat botulism, then treatment efficacy improves, but the therapies face limited cross-reactivity against multiple serotypes
Solution Approach 1:
The patent develops monoclonal antibody compositions that can neutralize multiple botulinum neurotoxin serotypes (A, B, E, F, and other emerging serotypes) simultaneously. This is achieved by combining antibodies with different specificities to create a universal treatment that addresses the limited cross-reactivity problem of single-antibody therapies.
Solution Approach 2:
The invention uses composite antibody compositions comprising multiple monoclonal antibodies with different specificities. These composite compositions are designed to target multiple serotypes of botulinum neurotoxins, thereby overcoming the limitation of single antibodies that only recognize one serotype.
2Reliability
If mass vaccination is implemented to prevent botulism, then population protection improves, but vaccination would prevent subsequent medicinal use of BoNT
Solution Approach 1:
The patent provides neutralizing antibody compositions that can be administered as post-exposure prophylaxis or treatment. This preliminary action approach allows individuals to receive protective antibodies after potential exposure to botulinum toxin, without the need for mass vaccination that would eliminate future therapeutic options.
3Reliability
If specific pharmaceutical agents are developed for botulism treatment, then treatment effectiveness improves, but no specific small molecule drugs currently exist
Solution Approach 1:
The patent replaces the concept of small molecule drugs with monoclonal antibody-based therapies. Instead of developing small molecule pharmaceutical agents, the invention uses biologic products (monoclonal antibodies) that can be produced through recombinant DNA technology and cell culture systems, offering an alternative pathway to effective treatment.
4Adaptability or versatility
If antibodies are designed to bind multiple serotypes, then broad-spectrum protection improves, but antibody cross-reactivity between serotypes is naturally limited
Solution Approach 1:
The patent combines multiple monoclonal antibodies with different specificities into single compositions. By merging antibodies that target different serotypes (e.g., anti-A, anti-B, anti-E, anti-F), the composition achieves broad-spectrum protection that no single antibody could provide alone.
Data Source
AI summary
The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.